This rather late notice relates to dilution resulting from the November 2019 $16.5Mil cap raise at 20c/share - Carestream did not participate in that or the subsequent 2020 14c/share cap raise.
Gilant, i agree with your thoughts on Carestream global sales agreement - they have done SFA to promote sales of the Nano IMO. Wondering when MX1 might give us an update on FDA application filing for the ROVER? From memory it was undergoing final electrical safety testing in early April and filing was expected within a couple of weeks??? according to March2020 quarter conference call of MD on 9th April 2020.
There has been a similar deathly silence on their search for a senior Marketing appointment flagged in the December 2019 quarterly report. Since that time they have appointed David Knox as a director but have not flagged a specific marketing role for him.
MX1 board and management need to improve accountability to shareholders IMO
MX1 Price at posting:
13.5¢ Sentiment: Hold Disclosure: Held
